

Original Research Article

PREVALENCE AND PATTERN OF EXTENDED SPECTRUM BETA-LACTAMASES (ESBL) PRODUCING *Klebsiella pneumoniae* IN BIOLOGICAL SPECIMEN AT A TERTIARY HOSPITAL

ABSTRACT

Aim: The study was carried out to assess the distribution and pattern of ESBL producing *Klebsiella pneumoniae* in specimen analysed at the Microbiology laboratory of a tertiary healthcare center.

Study Design: Cross-sectional study

Place and Duration of Study: Department of Medical Microbiology, University of Port Harcourt Teaching Hospital, Rivers state, Nigeria carried out between January 2019 to June 2019

Method: Clinical specimen including blood, wound biopsy/aspirate, urine and sputum specimens were collected and processed according to standard methods. Blood agar, Cysteine Lactose Electrolyte Deficient agar (CLED) and MacConkey agar were used to culture the specimens to isolate *K. pneumoniae*. A confirmatory test was carried out on all suspected ESBL isolates using combination disks according to the CLSI guidelines.

Results: The study reports a prevalence rate of 34.7% (118/340) for ESBL-production among *K. pneumoniae* isolates in UPTH, Port Harcourt. Blood culture was found to have the highest proportion of *ESBL K. pneumoniae* (57.1%) while urine samples had the least proportion of *ESBL K. pneumoniae* growth (32.5%). There was no significant distribution of *ESBL K. pneumoniae* growth by age groups or gender among the patients sampled. However, the occurrence of *ESBL K. pneumoniae* was higher among in-patients (37.0%) compared to outpatients (28.7%).

Conclusion: The growth of *ESBL K. pneumoniae* was observed to be higher among inpatient subject indicative of the likelihood of high prevalence *ESBL K. pneumoniae* in hospital acquired infection. Therefore, there is a great need for urgent interventions in the areas of antimicrobial usage and infection prevention and control in our settings.

Keywords: antibiotics, prevalence, extended spectrum beta-lactamase, *klebsiella pneumoniae*

1.0 INTRODUCTION

Extended-spectrum beta-lactamases (ESBLs) are a heterogeneous group of plasmid-mediated bacterial enzymes that confer significant resistance to oxyimino-cephalosporin and monobactam antimicrobials.[1] They are however inhibited by beta-lactamase inhibitors such as clavulanic acid.[2] There is a global variation even in closely related regions of the prevalence of ESBLs. Reports have shown that ESBL-producing bacteria are prevalent in clinical and community settings with serious public health consequences.[3, 4] A study conducted by Mohammed *et al* in Maiduguri Nigeria, recorded a prevalence of 23.8% and 30.0% ESBL- producing *Escherichia coli* and *Klebsiella* spp, respectively.[5] *Klebsiella pneumoniae*, a gram negative bacillus, is one of the common pathogens associated with multiple drug resistance and an important source of transferable antibiotic resistance.[6] There has been a dramatic increase of ESBLs among clinical isolates caused by the Enterobacteriaceae in the last three decades.[7, 8] However, in the last two decades, ESBL has emerged creating a gradual global challenge in both the healthcare settings and local communities. Studies have shown a strong association between gastrointestinal carriage of *K. pneumoniae* with subsequent infections in hospitalized patients and ~5% of colonized

patients went on to get an infection.[9][10] The consequences of ESBL (Extended-Spectrum Beta-Lactamase) *Klebsiella* infections in hospital settings can be significant and potentially life-threatening and are associated with Treatment difficulties, Spread of infection, especially in high-risk areas such as intensive care units, Increased morbidity and mortality, while increasing the Length of stay and costs and exacerbating the current challenge of antimicrobial resistance.[11–14] Therefore, it is important to implement effective infection control measures, use antibiotics judiciously, and promote the development of new treatments for ESBL *Klebsiella* infections to reduce their impact in hospital settings. The current study was carried out to assess the distribution and pattern of ESBL producing *Klebsiella pneumoniae* in specimen analysed at the Microbiology laboratory of a tertiary healthcare center.[15]

2.0 METHODS

2.1 Study Area

This study was conducted at the University of Port Harcourt Teaching Hospital (UPTH) located at 4°53'59.4N, 6° 55'45.6E in Rivers State, Nigeria. The State is a cosmopolitan area full of industrial activities especially in the oil and gas sector. The State has a population of 5 million people and is bounded on the South by the Atlantic Ocean, to the North by Imo, Abia and Anambra States, the East by Akwa-Ibom State and to the West by Bayelsa and Delta States. It is home to 3 major indigenous ethnic groups: Ijaw, Ikwerre and Ogoni. People from diverse cultural and ethnic backgrounds also live and work in the State. The University of Port Harcourt Teaching Hospital has an estimated bed capacity of 830 and an estimated 200,000 patients are seen annually. It is a tertiary healthcare institution with specialist consultants in various medical specialties that serves as a referral centre in Rivers State and neighbouring States including Bayelsa, Imo and Abia.

2.2 Study Population

The study population included all individuals attending the outpatient clinic and those on admission at the different wards of the study centre from whom various clinical specimens were collected. The individuals selected for the study included those that were recommended for microbiological investigations by the attending physicians.

2.3 Sample size

The sample size was determined using the Fischer's formula[16], $n = (Z^2pq)/d^2$, where Z is standard deviation corresponding to a specific confidence interval = 1.96 (at confidence interval 95%), p= the prevalence of ESBLs from a similar study[8] = 28.0% (0.331), q= 1.0-p, and d is degree of accuracy desired (usually set at 0.05). Therefore, $n = 3.84 \times 0.28 \times 0.72/0.0025 = 309.78 + 10\%$ attrition for incomplete data = 340.76.

2.4 Sampling Method

Patients from whom *Klebsiella pneumoniae* were isolated from their clinical specimens (urine, wound biopsies/aspirates, blood and sputum) at the UPTH Medical Microbiology and Parasitology Laboratory between January and June 2019, were selected by systematic random sampling based on sampling interval $k = N/n$ where N= 1600 (Estimated number of individuals referred for microbiological examination at the study center) and n = 340 (required sample size).

2.5 Specimen collection and analysis

Clinical and basic demographic information were obtained from selected patients using a PROFORMA data collection sheet. The information collected included age, gender, ward/clinic and specimen types. The specimen collected included wound aspirate, urine, blood and sputum specimen and all specimen were processed according to standard procedures as previously described.[17] The ESBL confirmatory test was carried out on all the suspected ESBL isolates using the combination disks according to the CLSI guidelines.

2.6 Data analysis

The data were analyzed using the Epi Info v 7 software and presented in tables or charts as appropriate. Variables such as sex, age group, wards, and departments were expressed as frequencies and proportions. The Chi-square statistic was used to compare the distribution of ESBL and non ESBL- producing isolates by gender, age groups and patient types. All analyses were done at a 95% confidence interval and a p-value of less than 0.05 was considered significant.

2.7 Ethical Consideration

Ethical approval to carry out the study was obtained from the Ethical committee of University of Port-Harcourt teaching hospital. Willing informed consent was obtained from each of the patients before they were included into the study.

3.0 RESULTS

A total of 340 isolates were obtained from specimen collected from patients within a six-month period (January to June 2019). Table 1 shows the demographic distribution of the patients with *Klebsiella pneumoniae* positive specimen. Of the 340 *K. pneumoniae*, 127 (37.4%) were from male subjects and 213 (62.6%) were from female subjects. The age distribution showed that 6 (1.8%) were between 40 – 49 years old, 10 (2.9%) were at least 60 years old, 14(4.1%) were at least 50 – 59 years old, 26 (7.6%) were less than 20 years old, 127 (37.4%) were between 30 – 39 years old and 157 (46.2%) were between 20 – 29 years old.

Table 1: Demographic characteristics of subjects with confirmed *Klebsiella pneumoniae* isolates

Variable	Frequency (n = 340)	Percentage
Gender		
Male	127	37.4
Female	213	62.6
Age Groups (years)		
< 20	26	7.6
20 – 29	157	46.2
30 – 39	127	37.4
40 – 49	6	1.8
50 – 59	14	4.1
>60	10	2.9

Figure 1 shows the distribution of the different specimen positive for *Klebsiella pneumoniae* growth. There were 7 (2.1%) sputum, 7 (2.1%) Blood culture, 83 (24.4%) wound aspirate/biopsies, and 243 (71.5%) urine samples.




Figure 1: Distribution of specimen positive for *K. pneumoniae* growth

Figure 2 shows that a 34.7% (n = 118) prevalence of ESBL producing *K. pneumoniae* isolates among the 340 *K. pneumoniae* isolates identified in the study.




Figure 2: Prevalence of ESBL -producing *Klebsiella pneumoniae*

Table 2 shows the distribution of ESBL *Klebsiella pneumoniae* producing isolates by the different specimen was not statistically significant in the different samples ($\chi^2 = 2.80$, $p = 0.4203$). The table showed that the highest proportion of ESBL producers was found in blood culture specimen (57.1%), followed by sputum samples (42.9%), wound aspirates/biopsies (38.6%) and urine samples (32.5%)

Table 2: Distribution of ESBL producing *Klebsiella pneumoniae* from different specimen.

Specimen	ESBL positive (n, %)	ESBL negative (n, %)	Total (n, %)	Chi-square (p-value)
Sputum	3(42.9)	4(57.1)	7(100.0)	

Blood Culture	4(57.1)	3(42.9)	7(100.0)	2.80 (0.4203)
Wound aspirate/biopsies	32(38.6)	51(61.4)	83(100.0)	
Urine	79(32.5)	164(67.5)	243(100.0)	

The distribution of the ESBL-producers by gender was not statistically significant ($\chi^2 = 0.23$, $p = 0.6248$). the data showed that ESBL *K. pneumoniae* distribution was higher in female subjects (35.75) compared to male subjects (33.1%). The findings also showed that the distribution of ESBL *K. pneumoniae* was highest in persons less than 20 years (42.3%), followed by persons between 30 – 39 years (36.2%), while the age group with the least distribution of ESBL *K. pneumoniae* was the persons between 50 – 59 years (28.6%), with persons between 40-49 years not having any growth of ESBL *K. pneumoniae*. However, The distribution of ESBL producing *K. pneumoniae* in the different age groups was not statistically significant ($\chi^2 = 4.31$, $p = 0.546$).

Table 3: Gender and Age-related distribution of *Klebsiella pneumoniae*

Variable	ESBL-positive (n, %)	ESBL-negative (n, %)	Total (n, %)	Chi-square (p-value)
Gender				
Male	42(33.1)	85(66.9)	127(100.0)	0.23 (0.6248)
Female	76(35.7)	137(64.3)	213(100.0)	
Age Groups (years)				
< 20	11(42.3)	15(57.7)	26(100.0)	4.31 (0.546)
20 – 29	54(34.4)	103(65.6)	157(100.0)	
30 – 39	46(36.2)	81(63.8)	127(100.0)	
40 – 49	0(0.0)	6(100.0)	6(100.0)	
50 – 59	4(28.6)	10(71.4)	14(100.0)	
>60	3(30.0)	7(70.0)	10(100.0)	

Table 4 shows the distribution of the ESBL-producing isolates and patient types, 37% of the inpatient subjects had ESBL *K. pneumoniae* compared to 28.7% in the outpatient subjects. However, the distribution of ESBL *K. pneumoniae* was not statistically significant ($\chi^2 = 2.05$, $p = 0.152$).

Table 4: Distribution of ESBL and Patient Types

Source	ESBL Positive n, (%)	ESBL Negative n, (%)	Total (n, %)	Chi-Square (p-value)
Inpatient	91(37.0)	155(63.0)	246(100.0)	2.05 (0.152)
Outpatient	27(28.7)	67(71.3)	94(100.0)	

DISCUSSION

Urine specimen had the highest proportion of *Klebsiella* growth (71.5%), followed by wounds/aspirates (24.4%), while sputum samples (2.1%) had the least proportion of *Klebsiella* growth. This is consistent with reports of studies that isolated *Klebsiella pneumoniae* in clinical settings, as similar studies report that urine samples and wound/aspirates were the most common sources of *Klebsiella pneumoniae* isolated in a variety of clinical settings.[9, 10, 18, 19]

There was a 34.7% prevalence of ESBL *klebsiella* among the 340 *klebsiella* isolates observed in the current study. The prevalence of ESBL producing *K. pneumoniae* was observed to be 34.7%. This was consistent with the findings of previous studies done by Adeyankinnu *et al.*, [20] and Kiratisin *et al.* [21]. The clinical samples were varied in distribution with urine as the highest in frequency 216 (63.5%) and blood culture as the least 3 (0.9%). This is not surprising because previous work done by Kiratisin *et al.* observed that ESBL- producing isolates were recovered majorly from urine specimens. The prevalence of ESBL-production among *K. pneumoniae* isolates in this study is 34.7%. This is comparable to the rates of 39.8% reported in Enugu, [22] 33.6% in Abuja, [23] 31.6% in Lagos, 35.3% in Zaria [24] and 30.0% in Maiduguri. Studies however have shown higher prevalence of ESBL producers as reported by Ogefere *et al.*, [22] and Egbebi *et al.*, in Benin, Southwest Nigeria, Saraswathi *et al.*, [25] Hyderabad in India with rates as high as 44.3%, 56.0%, and 50.0%, respectively among Gram-negative bacteria isolated in clinical settings. The observed difference may be attributed to the different study population and specimen used such as urine and wound swabs by Ogefere *et al.* The study by Egbebi *et al.*, used a double-disk synergy testing method for ESBL testing, while Saraswathi *et al.*, assessed only post-operative infected wounds. The comparability of high prevalence in many developing nations throughout the world compared to industrialized countries in Europe and North America is especially remarkable. *Klebsiella* spp. are of significant medical value among other Enterobacteriaceae because they exhibit the ESBL mechanism and are commonly identified in hospital and community infections that require medications.

Blood culture was found to have the highest proportion of ESBL *K. pneumoniae* while urine samples had the least proportion of ESBL *K. pneumoniae* growth. This is in agreement with reports of similar studies showing a relatively high occurrence of ESBL producing *K. pneumoniae* in clinical specimen ranging from 24.6% - 60%. [13, 19, 26, 27]

Similarly, the findings of the current study showed the occurrence of ESBL *K. pneumoniae* was higher among in-patients (37.0%) compared to outpatients (28.7%). A comparison of studies in developed nations report a 10% - 30% occurrence of ESBL *K. pneumoniae* growth in blood specimen [9, 19, 28, 29] compared to developing countries like Nigeria which report between 40% - 55% occurrence of ESBL *K. pneumoniae* growth in blood culture in hospital settings. [8, 30–32] The contrasting reports of ESBL *K. pneumoniae* growth in developed nations compared to developing nations is an indication of the effectiveness of antimicrobial prescription policies in developed countries compared to developing nations. Similarly, many hospital settings in developed nations tend to have better management and control of antimicrobial resistance in comparison to developing countries.

CONCLUSION

The study showed that blood culture specimens had the highest burden of ESBL *K. pneumoniae* growth. It was also observed that ESBL *K. pneumoniae* growth was not significantly associated with gender or age groups. The growth of ESBL *K. pneumoniae* was observed to be higher among inpatient subject indicative of the likelihood of high prevalence ESBL *K. pneumoniae* in hospital acquired infection. Therefore, there is a great need for urgent interventions in the areas of antimicrobial usage and infection prevention and control in hospital-based settings.

REFERENCES

- [1] Gazin M, Paasch F, Goossens H, et al. Current trends in culture-based and molecular detection of extended-spectrum- β -lactamase-harboring and carbapenem-resistant Enterobacteriaceae. *Journal of Clinical Microbiology* 2012; 50: 1140–1146.
- [2] Olowe O, Oladipo GO, A MO, et al. PREVALENCE OF EXTENDED SPECTRUM BETA-LACTAMASES (ESBLs) CARRYING GENES IN KLEBSIELLA SPP FROM CLINICAL SAMPLES AT ILE-IFE, SOUTH WESTERN NIGERIA. *Int J Pharm Med Bio Sc* 2012; 1: 129–138.

- [3] Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing *Klebsiella pneumoniae*, a key pathogen set for global nosocomial dominance. *Antimicrobial Agents and Chemotherapy* 2015; 59: 5873–5884.
- [4] Broberg CA, Palacios M, Miller VL. *Klebsiella*: A long way to go towards understanding this enigmatic jet-setter. *F1000Prime Rep*; 6. Epub ahead of print 2014. DOI: 10.12703/P6-64.
- [5] Mohammed Y, Gadzama GB, Zailani SB, et al. Characterization of extended-spectrum beta-lactamase from *Escherichia coli* and *Klebsiella* species from North Eastern Nigeria. *J Clin Diagnostic Res* 2016; 10: DC07-DC10.
- [6] Ramirez MS, Traglia GM, Lin DL, et al. Plasmid-Mediated Antibiotic Resistance and Virulence in Gram-Negatives: the *Klebsiella pneumoniae* Paradigm. *Microbiol Spectr*; 2. Epub ahead of print 3 October 2014. DOI: 10.1128/microbiolspec.plas-0016-2013.
- [7] Vading M, Naucler P, Kalin M, et al. Invasive infection caused by *Klebsiella pneumoniae* is a disease affecting patients with high comorbidity and associated with high long-term mortality. *PLoS One*; 13. Epub ahead of print 1 April 2018. DOI: 10.1371/JOURNAL.PONE.0195258.
- [8] Tanko N, Bolaji RO, Olayinka AT, et al. A systematic review on the prevalence of extended-spectrum beta lactamase-producing Gram-negative bacteria in Nigeria. *J Glob Antimicrob Resist* 2020; 22: 488–496.
- [9] Martin RM, Cao J, Brisse S, et al. Molecular Epidemiology of Colonizing and Infecting Isolates of *Klebsiella pneumoniae*. *mSphere*; 1. Epub ahead of print October 2016. DOI: 10.1128/msphere.00261-16.
- [10] Gorrie CL, Mirc Eta M, Wick RR, et al. Gastrointestinal Carriage Is a Major Reservoir of *Klebsiella pneumoniae* Infection in Intensive Care Patients. *Clin Infect Dis* 2017; 65: 208–215.
- [11] Marder EP, Cieslak PR, Cronquist AB, et al. Incidence and trends of infections with pathogens transmitted commonly through food and the effect of increasing use of culture-independent diagnostic tests on surveillance—foodborne diseases active surveillance network, 10 U.S. Sites, 2013–2016. *MMWR Morb Mortal Wkly Rep* 2017; 66: 397–403.
- [12] Salazar-Vizcaya L, Atkinson A, Kronenberg A, et al. The impact of public health interventions on the future prevalence of ESBL-producing *Klebsiella pneumoniae*: a population based mathematical modelling study. *BMC Infect Dis* 2022; 22: 1–10.
- [13] George A. Antimicrobial resistance, trade, food safety and security. *One Heal* 2018; 5: 6–8.
- [14] Adzitey F, Assoah-Peprah P, Teye GA. Whole-genome sequencing of *Escherichia coli* isolated from contaminated meat samples collected from the Northern Region of Ghana reveals the presence of multiple antimicrobial resistance genes. *J Glob Antimicrob Resist* 2019; 18: 179–182.
- [15] Zhang X, Zeng Q, Cai W, et al. Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. *BMC Public Health* 2021; 21: 1–10.
- [16] Khairuzzaman MQ. Essential Medical Statistics. 2016; 4: 64–75.
- [17] Network ARS and R. *Standard Operating Procedures Bacteriology*. 2019.
- [18] Saha AK. Pattern of Antimicrobial Susceptibility of *Klebsiella Pneumoniae* Isolated from Urinary Samples in urinary Tract Infection in a Tertiary Care Hospital, Kishanganj, Bihar, 5 Years' Experience. Epub ahead of print 2019. DOI: 10.21276/ijcmr.2019.6.12.42.
- [19] Ferreira RL, Da Silva BCM, Rezende GS, et al. High prevalence of multidrug-resistant *klebsiella pneumoniae* harboring several virulence and β -lactamase encoding genes in a brazilian intensive care unit. *Front Microbiol*; 10. Epub ahead of print 2019. DOI:

- 10.3389/FMICB.2018.03198/FULL.
- [20] Adeyankinnu FA, Motayo BO, Akinduti A, et al. A multicenter study of beta-lactamase resistant escherichia coli and klebsiella pneumoniae reveals high level chromosome mediated extended spectrum β lactamase resistance in ogun state, Nigeria. *Interdiscip Perspect Infect Dis*; 2014. Epub ahead of print 2014. DOI: 10.1155/2014/819896.
 - [21] Kiratisin P, Apisarnthanarak A, Laesripa C, et al. Molecular characterization and epidemiology of extended-spectrum- β - lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. *Antimicrob Agents Chemother* 2008; 52: 2818–2824.
 - [22] Ogefere HO, Aigbiremwen PA, Omoregie R. Extended-spectrum beta-lactamase (esbl)–producing gram-negative isolates from urine and wound specimens in a tertiary health facility in southern nigeria. *Trop J Pharm Res* 2015; 14: 1089–1094.
 - [23] Akanbi BO, Ojonuba BD, Njoku R. Detection of Extended Spectrum β -Lactamase Producing Klebsiella pneumoniae and Escherichia coli in Two Hospitals in the Federal Capital Territory, Abuja, Nigeria. *Open J Med Microbiol* 2013; 03: 207–212.
 - [24] Olonitola O, Olayinka A, Inabo H, et al. Olonitola.pdf. *Int J Biol Chem Sci* 2007; 1: 181–185.
 - [25] Saraswathi R, Velayutharaj A, Noyal M. Occurrence of Extended Spectrum Beta Lactamase (ESBL) Producers in Post Operative Wound Infection. *Sch J Appl Med Sci* 2015; 3: 995–999.
 - [26] Sianipar O, Asmara W, Dwiprahasto I, et al. Mortality risk of bloodstream infection caused by either Escherichia coli or Klebsiella pneumoniae producing extended-spectrum β -lactamase: A prospective cohort study. *BMC Res Notes* 2019; 12: 1–7.
 - [27] Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis* 2019; 19: 56–66.
 - [28] Su X, Yan X, Li Y, et al. Identification of extended-spectrum beta-lactamase (CTX-M)-producing Klebsiella pneumoniae belonging to ST37, ST290, and ST2640 in captive giant pandas. *BMC Vet Res*; 18. Epub ahead of print 1 December 2022. DOI: 10.1186/S12917-022-03276-7.
 - [29] Rostamian M, Kadivar S, Kooti S, et al. Prevalence of Extended-Spectrum Beta-Lactamase in Gram Negative Bacteria Isolated from Kermanshah Medical Centers: A Systematic Review and Meta-Analysis. *Iran J Med Microbiol* 2022; 16: 490–505.
 - [30] Mohammed Y, Gadzama GB, Zailani SB, et al. Characterization of Extended-Spectrum Beta-lactamase from Escherichia coli and Klebsiella Species from North Eastern Nigeria. *J Clin Diagn Res* 2016; 10: DC07.
 - [31] Motayo BO, Akinduti PA, Adeyakinu FA, et al. Antibigram and plasmid profiling of carbapenemase and extended spectrum Beta-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae in Abeokuta, South western, Nigeria. *Afr Health Sci* 2013; 13: 1091.
 - [32] Soge OO, Queenan AM, Ojo KK, et al. CTX-M-15 extended-spectrum β -lactamase from Nigerian Klebsiella pneumoniae. *J Antimicrob Chemother* 2006; 57: 24–30.